Summary
Background Patients with pre-existing cirrhosis are considered at increased risk of severe coronavirus disease 2019 (COVID-19) but the clinical course in these patients has not yet been reported. This study aimed to provide a detailed report of the clinical characteristics and outcomes among COVID-19 patients with pre-existing cirrhosis.
Methods In this retrospective, multicenter cohort study, we consecutively included all adult inpatients with laboratory-confirmed COVID-19 and pre-existing cirrhosis that had been discharged or had died by 24 March 2020 from 16 designated hospitals in China.
Demographic, clinical, laboratory and radiographic findings on admission, treatment, complications during hospitalization and clinical outcomes were collected and compared between survivors and non-survivors.
Findings Twenty-one patients were included consecutively in this study, of whom 16 were cured and 5 died in hospital. Seventeen patients had compensated cirrhosis and hepatitis B virus infection was the most common etiology. Lymphocyte and platelet counts were lower, and direct bilirubin levels were higher in patients who died than those who survived (p= 0·040, 0·032, and 0·006, respectively). Acute respiratory distress syndrome and secondary infection were both the most frequently observed complications. Only one patient developed acute on chronic liver failure. Of the 5 non-survivors, all patients developed acute respiratory distress syndrome and 2 patients progressed to multiple organ dysfunction syndrome.
Interpretation Lower lymphocyte and platelet counts, and higher direct bilirubin level might represent poor prognostic indicators in SARS-CoV-2-infected patients with pre-existing cirrhosis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04329559
Funding Statement
None
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Joint first authors
↵† Joint senior authors
Author contributions: Concept and design: Xiaolong Qi; Acquisition and interpretation of data: Bin Xiong, Jianwen Wang, Xinyu Li, Jindong Shi, Hongqiu Pan, Shengqiang Zou, Hongguang Zhang, Zhenhuai Chen, Fujian Li, Yan Luo, Mei Mei, Huiling Liu, Zhengyan Wang, Jinlin Li, Hua Yang, Huihua Xiang, Xiaodan Li, Tao Liu, Ming-Hua Zheng, Chuan Liu, Yifei Huang, Dan Xu, Qing He, Ye Gu, Guo Zhang, Chuxiao Shao, Dengxiang Liu, Lin Zhang, Xun Li, Zicheng Jiang, Fengmei Wang; Drafting of the manuscript: Yanna Liu, Jitao Wang, Xiaolong Qi. Critical revision of the manuscript: Don C. Rockey, Jonathan A. Fallowfield, Tetsuo Takehara, Norifumi Kawada.
Conflicts of interest: The authors have declared no conflict of interest related to the study.
Financial support: None.
Data Availability
I confirm the availability of all data referred to in the manuscript
